Radiosynthesis and evaluation of talazoparib and its derivatives as parp-1-targeting agents

Keyphrases

• Biodistribution Studies 10%
• Bromo Derivatives 20%
• Chiral Purity 10%
• Competitive Binding Assay 10%
• Critical Enzymes 10%
• DNA Repair Capacity 10%
• FDA-approved Drugs 10%
• High Affinity 10%
• In Vivo Evaluation 10%
• Iodo Derivatives 20%
• Molar Activity 10%
• Multiple Steps 10%
• Non-invasive Imaging 10%
• Olaparib 20%
• PARP Inhibitor (PARPi) 100%
• PC-3 10%
• Racemic Mixture 10%
• Raclopride 10%
• Radiochemical Purity 10%
• Radioligand 10%
• Radiosynthesis 100%
• Rucaparib 10%
• Talazoparib 100%
• Targeted Agents 100%
• Targeted Radiotherapy 20%
• Therapeutic Radionuclides 10%
• Tritium 10%
• Tumor 10%
• Tumor Model 10%
• Tumor Uptake 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Biodistribution 11%
• Fluorine 18 33%
• Neoplasm 22%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 1 100%
• Olaparib 22%
• Raclopride 11%
• Radioisotope 11%
• Radioligand 11%
• Rucaparib 11%
• Talazoparib 100%
• Tritium 11%
• Tumor Model 11%